Tokyo Tape
Sign in
← Nihon Chouzai

Quarterly report · Q2

3341.TEDINET S100S9Q4
Period2023-04-01 → 2023-09-30
Filed2023-11-14
StandardJapan GAAP
ConsolidatedYes
Data checks14 of 14 passed
Key figures · 46
MetricValuePeriodScopeSource row
Revenue¥166.3bn2023-04-01 → 2023-09-30Cons.Net sales
Revenue¥313.3bn2022-04-01 → 2023-03-31Cons.Net sales (5-year summary)
Revenue¥152.3bn2022-04-01 → 2022-09-30Cons.Net sales
Operating income¥3.4bn2023-04-01 → 2023-09-30Cons.Operating income
Operating income¥2.8bn2022-04-01 → 2022-09-30Cons.Operating income
Ordinary income¥3.4bn2023-04-01 → 2023-09-30Cons.Ordinary income
Ordinary income¥7.7bn2022-04-01 → 2023-03-31Cons.Ordinary income loss (5-year summary)
Ordinary income¥2.8bn2022-04-01 → 2022-09-30Cons.Ordinary income
Profit before tax¥3.4bn2023-04-01 → 2023-09-30Cons.Income before income taxes
Profit before tax¥2.9bn2022-04-01 → 2022-09-30Cons.Income before income taxes
Net income (owners)¥1.7bn2023-04-01 → 2023-09-30Cons.Profit loss attributable to owners of parent
Net income (owners)¥4.5bn2022-04-01 → 2023-03-31Cons.Profit loss attributable to owners of parent (5-year summary)
Net income (owners)¥1.6bn2022-04-01 → 2022-09-30Cons.Profit loss attributable to owners of parent
Net income¥1.7bn2023-04-01 → 2023-09-30Cons.Profit loss
Net income¥1.6bn2022-04-01 → 2022-09-30Cons.Profit loss
Total assets¥193.5bnat 2023-09-30Cons.Assets
Total assets¥185.3bnat 2023-03-31Cons.Assets
Total assets¥187.6bnat 2022-09-30Cons.Total assets (5-year summary)
Total liabilities¥135.6bnat 2023-09-30Cons.Liabilities
Total liabilities¥128.8bnat 2023-03-31Cons.Liabilities
Net assets / equity¥57.9bnat 2023-09-30Cons.Net assets
Net assets / equity¥56.5bnat 2023-03-31Cons.Net assets
Net assets / equity¥54.0bnat 2022-09-30Cons.Net assets (5-year summary)
Cash and deposits¥22.2bnat 2023-09-30Cons.Cash and deposits
Cash and deposits¥23.8bnat 2023-03-31Cons.Cash and deposits
Cash & equivalents¥22.2bnat 2023-09-30Cons.Cash and cash equivalents
Cash & equivalents¥23.8bnat 2023-03-31Cons.Cash and cash equivalents
Cash & equivalents¥21.5bnat 2022-09-30Cons.Cash and cash equivalents
Cash & equivalents¥25.5bnat 2022-03-31dCons.Cash and cash equivalents
Operating cash flow¥11.9bn2023-04-01 → 2023-09-30Cons.Net cash provided by used in operating activities
Operating cash flow¥7.5bn2022-04-01 → 2023-03-31Cons.Net cash provided by used in operating activities (5-year summary)
Operating cash flow¥1.0bn2022-04-01 → 2022-09-30Cons.Net cash provided by used in operating activities
Investing cash flow−¥8.0bn2023-04-01 → 2023-09-30Cons.Net cash provided by used in investment activities
Investing cash flow−¥10.0bn2022-04-01 → 2023-03-31Cons.Net cash provided by used in investing activities (5-year summary)
Investing cash flow−¥7.6bn2022-04-01 → 2022-09-30Cons.Net cash provided by used in investment activities
Financing cash flow−¥5.4bn2023-04-01 → 2023-09-30Cons.Net cash provided by used in financing activities
Financing cash flow¥713m2022-04-01 → 2023-03-31Cons.Net cash provided by used in financing activities (5-year summary)
Financing cash flow¥2.5bn2022-04-01 → 2022-09-30Cons.Net cash provided by used in financing activities
EPS (basic)¥58.442023-04-01 → 2023-09-30Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥36.382023-07-01 → 2023-09-30dCons.Basic earnings loss per share (5-year summary)
EPS (basic)¥148.922022-04-01 → 2023-03-31Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥53.662022-04-01 → 2022-09-30Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥40.622022-07-01 → 2022-09-30dCons.Basic earnings loss per share (5-year summary)
Equity ratio29.9%at 2023-09-30Cons.Equity to asset ratio (5-year summary)
Equity ratio30.5%at 2023-03-31Cons.Equity to asset ratio (5-year summary)
Equity ratio28.8%at 2022-09-30Cons.Equity to asset ratio (5-year summary)

Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.

Segments · 37
SegmentItemPeriodValue
Reconciling Itemsreconcilingrevenue2023-04-01 → 2023-09-30−¥6.7bn
Reconciling Itemsreconcilingrevenue intersegment2023-04-01 → 2023-09-30−¥6.7bn
Reconciling Itemsreconcilingsegment profit2023-04-01 → 2023-09-30−¥3.5bn
jpcrp040300-q2r_E05422-000Dispensing Pharmacy Businessreportable segmentrevenue2023-04-01 → 2023-09-30¥147.6bn
jpcrp040300-q2r_E05422-000Dispensing Pharmacy Businessreportable segmentrevenue external2023-04-01 → 2023-09-30¥147.6bn
jpcrp040300-q2r_E05422-000Dispensing Pharmacy Businessreportable segmentsegment profit2023-04-01 → 2023-09-30¥6.0bn
jpcrp040300-q2r_E05422-000Medical Professional Staffing And Placement Businessreportable segmentrevenue2023-04-01 → 2023-09-30¥4.9bn
jpcrp040300-q2r_E05422-000Medical Professional Staffing And Placement Businessreportable segmentrevenue external2023-04-01 → 2023-09-30¥4.9bn
jpcrp040300-q2r_E05422-000Medical Professional Staffing And Placement Businessreportable segmentrevenue intersegment2023-04-01 → 2023-09-30¥14m
jpcrp040300-q2r_E05422-000Medical Professional Staffing And Placement Businessreportable segmentsegment profit2023-04-01 → 2023-09-30¥698m
jpcrp040300-q2r_E05422-000Pharmaceutical Manufacturing And Sales Businessreportable segmentrevenue2023-04-01 → 2023-09-30¥20.5bn
jpcrp040300-q2r_E05422-000Pharmaceutical Manufacturing And Sales Businessreportable segmentrevenue external2023-04-01 → 2023-09-30¥13.8bn
jpcrp040300-q2r_E05422-000Pharmaceutical Manufacturing And Sales Businessreportable segmentrevenue intersegment2023-04-01 → 2023-09-30¥6.7bn
jpcrp040300-q2r_E05422-000Pharmaceutical Manufacturing And Sales Businessreportable segmentsegment profit2023-04-01 → 2023-09-30¥167m
Total Of Reportable Segments And Otherssegment totalrevenue2023-04-01 → 2023-09-30¥173.0bn
Total Of Reportable Segments And Otherssegment totalrevenue external2023-04-01 → 2023-09-30¥166.3bn
Total Of Reportable Segments And Otherssegment totalrevenue intersegment2023-04-01 → 2023-09-30¥6.7bn
Total Of Reportable Segments And Otherssegment totalsegment profit2023-04-01 → 2023-09-30¥6.9bn
Reconciling Itemsreconcilingrevenue2022-04-01 → 2022-09-30−¥7.0bn
Reconciling Itemsreconcilingrevenue intersegment2022-04-01 → 2022-09-30−¥7.0bn
Reconciling Itemsreconcilingsegment profit2022-04-01 → 2022-09-30−¥3.3bn
jpcrp040300-q2r_E05422-000Dispensing Pharmacy Businessreportable segmentrevenue2022-04-01 → 2022-09-30¥136.2bn
jpcrp040300-q2r_E05422-000Dispensing Pharmacy Businessreportable segmentrevenue external2022-04-01 → 2022-09-30¥136.2bn
jpcrp040300-q2r_E05422-000Dispensing Pharmacy Businessreportable segmentrevenue intersegment2022-04-01 → 2022-09-30¥1m
jpcrp040300-q2r_E05422-000Dispensing Pharmacy Businessreportable segmentsegment profit2022-04-01 → 2022-09-30¥6.0bn
jpcrp040300-q2r_E05422-000Medical Professional Staffing And Placement Businessreportable segmentrevenue2022-04-01 → 2022-09-30¥4.0bn
jpcrp040300-q2r_E05422-000Medical Professional Staffing And Placement Businessreportable segmentrevenue external2022-04-01 → 2022-09-30¥4.0bn
jpcrp040300-q2r_E05422-000Medical Professional Staffing And Placement Businessreportable segmentrevenue intersegment2022-04-01 → 2022-09-30¥9m
jpcrp040300-q2r_E05422-000Medical Professional Staffing And Placement Businessreportable segmentsegment profit2022-04-01 → 2022-09-30¥500m
jpcrp040300-q2r_E05422-000Pharmaceutical Manufacturing And Sales Businessreportable segmentrevenue2022-04-01 → 2022-09-30¥19.2bn
jpcrp040300-q2r_E05422-000Pharmaceutical Manufacturing And Sales Businessreportable segmentrevenue external2022-04-01 → 2022-09-30¥12.2bn
jpcrp040300-q2r_E05422-000Pharmaceutical Manufacturing And Sales Businessreportable segmentrevenue intersegment2022-04-01 → 2022-09-30¥7.0bn
jpcrp040300-q2r_E05422-000Pharmaceutical Manufacturing And Sales Businessreportable segmentsegment profit2022-04-01 → 2022-09-30−¥396m
Total Of Reportable Segments And Otherssegment totalrevenue2022-04-01 → 2022-09-30¥159.3bn
Total Of Reportable Segments And Otherssegment totalrevenue external2022-04-01 → 2022-09-30¥152.3bn
Total Of Reportable Segments And Otherssegment totalrevenue intersegment2022-04-01 → 2022-09-30¥7.0bn
Total Of Reportable Segments And Otherssegment totalsegment profit2022-04-01 → 2022-09-30¥6.1bn

Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.

All source rows · 513
ItemContextValueUnit
Insurance income noiPrior1YTDDuration51000000JPY
Insurance income noiCurrentYTDDuration11000000JPY
Subsidy income noiPrior1YTDDuration21000000JPY
Subsidy income noiCurrentYTDDuration22000000JPY
Other noiPrior1YTDDuration161000000JPY
Other noiCurrentYTDDuration113000000JPY
Non operating incomePrior1YTDDuration544000000JPY
Non operating incomeCurrentYTDDuration477000000JPY
Interest expenses noePrior1YTDDuration133000000JPY
Interest expenses noeCurrentYTDDuration178000000JPY
Rent expense noePrior1YTDDuration218000000JPY
Rent expense noeCurrentYTDDuration197000000JPY
Other noePrior1YTDDuration156000000JPY
Other noeCurrentYTDDuration132000000JPY
Non operating expensesPrior1YTDDuration508000000JPY
Non operating expensesCurrentYTDDuration508000000JPY
Ordinary incomePrior1YTDDuration2849000000JPY
Ordinary incomeCurrentYTDDuration3367000000JPY
Gain on sales of noncurrent assets eiPrior1YTDDuration47000000JPY
Gain on sales of noncurrent assets eiCurrentYTDDuration51000000JPY
Compensation income eiPrior1YTDDuration120000000JPY
Compensation income eiCurrentYTDDuration32000000JPY
Extraordinary incomePrior1YTDDuration167000000JPY
Extraordinary incomeCurrentYTDDuration84000000JPY
Impairment loss elPrior1YTDDuration114000000JPY
Impairment loss elCurrentYTDDuration71000000JPY
Loss on sales of noncurrent assets elPrior1YTDDuration51000000JPY
Loss on sales of noncurrent assets elCurrentYTDDuration0JPY
Extraordinary lossPrior1YTDDuration166000000JPY
Extraordinary lossCurrentYTDDuration72000000JPY
Income before income taxesPrior1YTDDuration2850000000JPY
Income before income taxesCurrentYTDDuration3378000000JPY
Income taxes currentPrior1YTDDuration1094000000JPY
Income taxes currentCurrentYTDDuration1702000000JPY
Income taxes deferredPrior1YTDDuration148000000JPY
Income taxes deferredCurrentYTDDuration-71000000JPY
Income taxesPrior1YTDDuration1243000000JPY
Income taxesCurrentYTDDuration1630000000JPY
Profit lossPrior1YTDDuration1607000000JPY
Profit lossCurrentYTDDuration1748000000JPY
Profit loss attributable to owners of parentPrior1YTDDuration1607000000JPY
Profit loss attributable to owners of parentCurrentYTDDuration1748000000JPY
Profit lossPrior1YTDDuration1607000000JPY
Profit lossCurrentYTDDuration1748000000JPY
Remeasurements of defined benefit plans net of tax ociPrior1YTDDuration7000000JPY
Remeasurements of defined benefit plans net of tax ociCurrentYTDDuration2000000JPY
Other comprehensive incomePrior1YTDDuration7000000JPY
Other comprehensive incomeCurrentYTDDuration2000000JPY
Comprehensive incomePrior1YTDDuration1615000000JPY
Comprehensive incomeCurrentYTDDuration1750000000JPY

Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.

Data checks · 14 of 14 passed
balance sheet identityconsolidated 2023-03-31pass
balance sheet identityconsolidated 2023-09-30pass
dei present pass
period resolution pass
statement vs summary · net assetsconsolidated 2023-03-31pass
statement vs summary · net assetsconsolidated 2023-09-30pass
statement vs summary · net income attributable to parentconsolidated 2022-04-01/2022-09-30pass
statement vs summary · net income attributable to parentconsolidated 2023-04-01/2023-09-30pass
statement vs summary · operating cash flowconsolidated 2022-04-01/2022-09-30pass
statement vs summary · operating cash flowconsolidated 2023-04-01/2023-09-30pass
statement vs summary · revenueconsolidated 2022-04-01/2022-09-30pass
statement vs summary · revenueconsolidated 2023-04-01/2023-09-30pass
statement vs summary · total assetsconsolidated 2023-03-31pass
statement vs summary · total assetsconsolidated 2023-09-30pass